Lenacapavir PrEP PURPOSE 1: Wits RHI High Efficacy Study
Wits RHI's PURPOSE 1 study at CROI 2026 reveals lenacapavir PrEP's 99.93% efficacy for HIV prevention in young women, with analysis of rare breakthroughs. Key implications for South Africa.
higher-education-researchresearch-publication-newswits-rhi
